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Preclinical studies show that GABA exerts anti-diabetic effects in rodent models of
type 1 diabetes. Because little is known about its absorption and effects in humans,
we investigated the pharmacokinetics and pharmacodynamics of GABA in healthy
volunteers. Twelve subjects were subjected to an open-labeled, three-period trial
involving sequential oral administration of placebo, 2 g GABA once, and 2 g GABA three
times/day for 7 days, with a 7-day washout between each period. GABA was rapidly
absorbed (Tmax: 0.5∼ 1 h) with the half-life (t1/2) of 5 h. No accumulation was observed
after repeated oral GABA administration for 7 days. Remarkably, GABA significantly
increased circulating insulin levels in the subjects under either fasting (1.6-fold, single
dose; 2.0-fold, repeated dose; p < 0.01) or fed conditions (1.4-fold, single dose;
1.6-fold, repeated dose; p < 0.01). GABA also increased glucagon levels only under
fasting conditions (1.3-fold, single dose, p < 0.05; 1.5-fold, repeated dose, p < 0.01).
However, there were no significant differences in the insulin-to-glucagon ratio and no
significant change in glucose levels in these healthy subjects during the study period.
Importantly, GABA significantly decreased glycated albumin levels in the repeated dosing
period. Subjects with repeated dosing showed an elevated incidence of minor adverse
events in comparison to placebo or the single dosing period, most notably transient
discomforts such as dizziness and sore throat. However, there were no serious adverse
events observed throughout the study. Our data show that GABA is rapidly absorbed and
tolerated in human beings; its endocrine effects, exemplified by increasing islet hormonal
secretion, suggest potential therapeutic benefits for diabetes.
Keywords: GABA, pharmacokinetics, glucagon, insulin, glycated albumin
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disease, characterized
by progressive loss of functional β-cell mass, resulting from
insulitis, which leads to insulin deficiency, elevation of blood
glucose, and various complications associated with this disease
(Atkinson et al., 2014). An ideal effective therapy may require
two arms: β-cell regeneration and immunosuppressive effects.
However, none of the current therapies effectively achieve both
goals (Lernmark and Larsson, 2013; Atkinson et al., 2014).
Recently we and others have shown that gamma aminobutyric
acid (GABA) exerts β-cell regenerative and immunoregulatory
effects (Soltani et al., 2011; Prud’homme et al., 2013; Tian et al.,
2013; Purwana et al., 2014). Specifically, GABA stimulates β-
cell replication, protects β-cells against apoptosis, and attenuates
insulitis (Soltani et al., 2011; Tian et al., 2013; Prud’homme et al.,
2014; Purwana et al., 2014). These effects result in an enhanced
functional β-cell mass and, in mice, this can reverse disease
(Soltani et al., 2011). These favorable effects were first observed
in mice (Tian et al., 2004, 2014), but appear valid in humans as
demonstrated in vitro as well as in xenotransplanted human islets
(Tian et al., 2013; Purwana et al., 2014).
GABA, identified initially in the central nervous system, is
produced by pancreatic β-cells in large quantities (Adeghate and
Ponery, 2002). While acting as an inhibitory neurotransmitter
in the adult brain (Owens and Kriegstein, 2002), GABA exerts
excitatory trophic effects such as neuronal cell proliferation
and dendritic maturation in the developing brain (Represa and
Ben-Ari, 2005). GABA exerts its biological effects through the
activation of GABA receptors that are expressed in a variety of
peripheral tissues, and cells including pancreatic islet cells and
immune cells such as T and B lymphocytes (Tian et al., 2011).
Within an islet, GABA suppresses glucagon secretion by the α-
cells as a consequence of membrane hyperpolarization (Rorsman
et al., 1989; Braun et al., 2004) but, in contrast, it enhances
insulin secretion by the β-cells throughmembrane depolarization
(Rorsman et al., 1989; Dong et al., 2006; Bansal andWang, 2008).
In some Western countries, GABA is an amino acid health
care product and used as an added component of various foods
or a nonprescription drug, for various indications such as sleep
or anxiety disorders; and studies using GABA supplementation
in healthy individuals following daily GABA intakes up to 18 g
for 4 days or 120mg for 12 months indicated that GABA was
well tolerated (Cavagnini et al., 1980; Abdou et al., 2006; Yoto
et al., 2012)1. In China, GABA, which is listed in the Chinese
Pharmacopeia [National Drug Standards, Drug Standards No.
Abbreviations: GABA, γ-aminobutyric acid; T1D, type 1 diabetes; Cmax,
maximum concentration; PK, pharmacokinetics; PD, pharmacodynamics; FDA,
Food and Drug Administration; Tmax, time to maximum plasma concentration;
t1/2, terminal elimination half-life; CL/F, apparent clearance; V/F, apparent volume
of distribution; AUC0–4h, area under the curve from the time zero to 4 h;
AUC0–24h, area under the curve from the time zero to 24 h; AUC0–t, area
under the curve from the time zero to the last quantifiable concentration; AUCinf,
area under the curve from the time zero extrapolated to infinity; RA, ratio of
accumulation; ALT, alanine transaminase; AST, aspartate aminotransferase; GLP-1,
glucagon-like peptide-1.
1http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-foods-gen/documents/
document/ucm264254.pdf
WS-10001-(HD-0871)-2002], has been clinically used for other
indications such as hepatic coma rather than diabetes more than
decades.
Although GABA is administered in grams per day according
to drug label approved by China FDA, there is little information
available in the public domain with respect of GABA’s
pharmacokinetics (PK) and pharmacodynamics (PD) in humans.
In order to establish a GABA PK and PD profile in humans
which may facilitate researchers’ efforts to exam whether GABA
is effective of diabetes in humans, we conducted a phase 1 clinical
study which was open-labeled, three period, sequential study in
12 healthy subjects. The following oral treatments were applied:
placebo, single dose of 2 g GABA, or repeated dose of 2 g GABA
three times daily for 7 days, with a 7-day washout between each
period to evaluate the PK, PD, and safety profile.
MATERIALS AND METHODS
Subjects
A total of 12 healthy volunteers were recruited (6 male, 6
female, aged 26 ± 1 years, BMI 22 ± 0.5 Kg/m2; body weight
61.2 ± 2.2 Kg). One volunteer withdrew before the single dose
period. All subjects were not on any medication 2 weeks prior
to screening and had no blood donation within 3 months before
screening. The exclusion criteria were: abnormalities of physical
examination, laboratory tests, or electrocardiogram (ECG) in
screening, which may influence the results of the study; previous
or existing history of severe heart, liver, kidney, gastrointestinal,
nervous system, mental, or metabolic abnormalities, and
other diseases which can affect drug absorption, circulation,
metabolism, or excretion; history of alcoholism, smoking, or drug
abuse within the past 1 year; participation in any clinical drug
study within the past 30 days; any definite or suspected allergy or
family history of allergy to GABA or any other similar drugs.
Study Overview
This was a single-center, open-labeled, three-period (with fixed
sequence of assessments: placebo, single dose, repeated dose),
and self-controlled study (Supplementary Table 1). In period
1 (placebo period), blood was sampled on day 1 (2 g placebo
tablet dosing once at 8:00 AM) to obtain the baseline values. In
period 2 (single dose period), blood was sampled on day 8 (2 g
GABA tablet dosing once at 8:00 AM). In period 3 (repeated dose
period), blood was sampled on day 22 [2 g GABA tablet dosing
three times per day (8:00 AM, 12:00 AM, and 6:00 PM prior to
meals) from day 15 to day 21, then 2 g GABA tablet dosing last
time at 8:00 AM on day 22]. There were 7 days wash-out intervals
between two periods. Subjects were hospitalized for the entire
repeated-dose period, and had standardized food intake to avoid
eating foods known to contain high quantities of GABA (e.g.,
potatoes, soybeans) during the study. The GABA (or placebo)
tablets were from Shanghai Xinyi Pharmaceuticals CO., Ltd.
In each period, blood were sampled at pre-dose, 0.25, 0.5, 0.75,
1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose for PK and PD study.
Other laboratory tests are listed in Supplementary Table 1. All
these blood samples were collected from forearm vein.
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This study was approved by Institutional Review Board
of Huashan Hospital, and complied with the Declaration of
Helsinki. All volunteers signed the informed consent. The study
was conducted at the Phase1 Unit, Huashan Clinical Trial
Base (approved and certificated by China State Food and Drug
Administration).
This trial is registered with ClinicalTrials.gov, number
NCT01917760.
Safety Assessments
In each period, before 8:00 AM, subjects underwent physical
examination, 12-lead ECG, and detection of any adverse events
using open questions. Vital signs (blood pressure and heart
rate) and open questions for detecting adverse events were
performed at pre-dose, 4, and 12 h post-dose. Participants could
also report adverse events anytime during the study. At 24 h post-
dose, the participants were required to undergo safety analysis
including blood/urine routine tests, chemistry test, 12-lead ECG
and monitoring of adverse events. According to U.S. FDA, any
event which causes death, permanent damage, birth defects, or
requires hospitalization is defined as serious adverse event.
Pharmacokinetic Assessments
Blood samples for GABA detection were collected into a
precooled Vacutainer R© EDTA-plasma tubes at pre-dose and 0.25,
0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h after dosing on day 1,
8, and 22. Within 3min, plasma was prepared by centrifugation
(3000 g at 4◦C for 10min) and stored at−80◦C until analysis.
The determination of GABA levels was accomplished by the
Shanghai Center for Drug Metabolism and Pharmacokinetics
Research, Shanghai Institute of Materia Medica, Chinese
Academy of Sciences (Shanghai, China).
A Shimadzu High-Performance Liquid Chromatography
system LC-20AD (Shimadzu Corp., Japan) was used to perform
the separation of GABA and internal standard (d2-GABA). The
separation was achieved on a Phenomenex Luna HILIC column
(100mm× 3.0mm, 3µm; Phenomenex Corp., USA)maintained
at 40◦C. The mobile phase consisted of water–acetonitrile (20:80,
v/v) at a flow rate of 0.5mL/min. The injection volume was 5µL.
A triple quadruple mass spectrometer (ABI 4000 II, Applied
Biosystems Corp, USA) was equipped with an electrospray
ionization (ESI) for analytical detection. The ESI source was set in
positive ionization mode. Multiple reactions monitoring (MRM)
was used to monitor precursor to product ion transition of m/z
104→69 for GABA, and m/z 106→71 for d2-GABA with scan
time of 0.10 s per transition. The data acquisition and sample
quantification were operated using Analyst 1.6 software (Applied
Biosystems Corp, USA).
An aliquot of the plasma sample (100µL) was transferred to
an Eppendorf micro tube for processing. 25µL internal standard
(500 ng/mL d2-GABA) 100µL, methanol:water (1:1, v/v) and
500µL acetonitrile were added and vortex-mixed for 1min.
After centrifugation for 10min at 13,000 rpm, a 5µL aliquot of
the supernatant was injected onto the LC–MS/MS system for
analysis.
The calibration range was 5.0–1000 ng/mL in plasma. The
extraction recovery of GABA at the low, middle and high level
of quality control was 92.7, 91.5, and 98.2%, respectively. The
precision (RSD) and accuracy (relative bias) of the method were
evaluated to be within 9.9% and from−0.9 to 4.3%.
The PK parameters for GABA were calculated after
substratction of baseline GABA concentration and estimated
from plasma samples, by means of standard non-compartmental
methods using the WinNonlin software (Version 4.1, Pharsight
Corp, USA). The maximum plasma concentration (Cmax) and
the corresponding time (Tmax) were determined directly from
the concentration-time profiles during the three periods. The
areas under the concentration-time curves from zero to 24 h
(AUC0–24h) and to 4 h (AUC0–4h) were calculated using the
linear trapezoidal rule. Other PK parameters assessed included
oral clearance (CL/F), apparent volume of distribution (V/F),
ratio of accumulation (RA), area under the curve from the time
zero extrapolated to infinity (AUCinf).
Pharmacodynamic Assessments
GLP-1 and Glucagon
Onemilliliter blood sample for GLP-1 (active form) and glucagon
detection was collected into a precooled Vacutainer R© EDTA-
plasma tube that contained Sitagliptin (Sigma S8576, final blood
concentration was 100µmol/L) and Aprotinin (Sigma A1153,
final blood concentration was 250 KIU/ml) at pre-dose, 0.25, 0.5,
1, 2, 4, 6, 8, 10, 12, and 24 h post-dose from subjects during the
three periods as PK analysis. Immediately, tubes were inverted
to mix followed by immediate centrifugation (3000 g at 4◦C for
10min) and storage at −80◦C until analysis. Plasma glucagon
concentrations were measured by ELISA (Mercodia, Catalog No.
10-1271-01). Plasma GLP-1 (active form) concentrations were
also measured by ELISA (Millipore, Catalog No. EGLP-35K).
Insulin, C-peptide, and Blood Glucose
0.5ml blood sample for insulin and c-peptide detection was
collected into a Vacutainer R© serum separation tube at pre-dose,
0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, and 24 h post-dose from
subjects during the three periods as PK analysis. Concurrently,
0.5ml blood sample for blood glucose detection was collected
into a Vacutainer R© glucose tube that contained sodium fluoride.
Serum insulin and c-peptide concentrations were measured
by a electrochemiluminescence immunoassay technique (Roche
Elecsys 2010). Plasma glucose levels were measured by a glucose
oxidase method (Abbott C8000 analyzer).
The area under the concentration-time curve of GLP-1,
glucagon, insulin, c-peptide and blood glucose levels from the
time zero to 4 h (AUC0–4h) and to 24 h (AUC0–24h) were
calculated using the trapezoidal rule.
Glycated Albumin
Glycated albumin was measured by enzymatic assay on day −2,
day 15, and day 23 (Asahi Kasei Corporation, Japan. Lucica™
GA-L assay kit). Day −2 was the screening day. Day 15 was
the beginning day of the repeated dose period. Day 23 was the
sampling day of the repeated dose period.
Statistical Methods
Descriptive statistics of means and standard error (SE) were
calculated for continuous parameters, as well as frequencies
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and percentages for categorical parameters. AUC were
logarithmically transformed before analysis and then subjected
to ANOVA. If data were not normally distributed or did not met
the homogeneity of variances, nonparametric tests were used
for comparisons among multiple groups. Data were processed
using GraphPad Prism version 6.0 (GraphPad Software, Inc, La
Jolla, CA) and Statistical Product and Service Solutions (SPSS)
version 19.0 (SPSS, Inc, Chicago, IL). All tests were two-sided,
with P < 0.05 considered statistically significant.
RESULTS
Pharmacokinetic Profile
Individual concentration-time profiles of GABA following
oral administration in the three periods were determined
(Figures 1A–C). Given the obvious variations among the study
subjects in each period, data are presented as geometric mean
± SE (Figure 1D). When the concentration-time profiles of
GABA were presented as area under the curve (AUC), the
AUC0–4h and AUC0–24h of a single dose and repeated doses
were statistically significant compared to the placebo control
(AUC0–4h: single dose vs. control = 1042.92 ± 221.95 vs.
48.47 ± 2.46 h·ng/ml, p < 0.001; repeated dose vs. control
= 1246.54 ± 396.46 vs. 48.47 ± 2.46 h·ng/ml, p < 0.001.
AUC0–24h: single dose vs. control = 1451.68 ± 243.12 vs.
272.85 ± 14.28 h·ng/ml, p < 0.001; repeated dose vs. control
= 1778.69 ± 433.21 vs. 272.85 ± 14.28 h·ng/ml, p < 0.001).
This indicates that GABA was rapidly absorbed, with maximum
plasma concentrations achieved approximately 1–1.5 h after an
oral dose, and subsequent mean elimination half-life in a range
of 5–5.2 h. Additional derived pharmacokinetic parameters are
summarized in Table 1. As shown, oral GABA administration
both the single dose and repeated dose reached a comparable
Cmax (688 vs. 767 ng/ml), suggesting that GABA reached a
Cmax that was not dependent on the frequency of oral dosing.
The cumulative coefficient was 1.11, which suggests almost no
accumulation phenomenon during a course of oral GABA of
2 g administered three times per day for 7 consecutive days.
There were no significant differences of the PK profiles observed
between male and female volunteers.
Pharmacodynamic Effects
There were no statistical differences in blood glucose, including
the postprandial glucose levels, amongst the placebo, single dose,
FIGURE 1 | Concentration-time profiles of GABA. Individual concentration-time curves of GABA in the three periods (A, repeated dose period; B, single dose
period; C, placebo period). Total concentration-time curves of GABA in the three periods, data are presented as geomean ± SE (D).
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and repeated dose periods (Figure 2A), suggesting that oral
GABA administration does not alter instantaneous blood glucose
levels in healthy subjects, either under fasting or fed conditions.
Remarkably, corresponding to Tmax of GABA, an increase in
insulin levels was observed (Figure 2B). The insulin AUC0–4h
(fasting period) in the repeated dose period was higher than
that of single dose and placebo periods, and insulin AUC0–4h
of single dose period was higher than that of placebo period
(AUC0–4h: placebo vs. single dose = 94.91 ± 6.33 vs. 147.22
± 13.95 h·pmol/L, p < 0.01; placebo vs. repeated dose = 94.91
± 6.33 vs. 185.80 ± 12.82 h·pmol/L, p < 0.01; single dose vs.
repeated dose = 147.22 ± 13.95 vs. 185.80 ± 12.82 h·pmol/L,
p < 0.05). Furthermore, at the time points corresponding to
meals (Figure 2B, 2 h after lunch, 2 h after supper), circulating
insulin levels were higher in repeated dose and the single dose
periods than that of the placebo period (2 h after lunch: repeated
dose vs. placebo= 599.18± 32.46 vs. 375.71± 48.33%, p < 0.01;
single dose vs. placebo = 514.23 ± 32.81 vs. 375.71 ± 48.33%,
p < 0.05. Two hours after supper: repeated dose vs. placebo =
449.35 ± 42.66 vs. 304.17 ± 29.14%, p < 0.01; single dose vs.
placebo = 415.47 ± 24.26 vs. 304.17 ± 29.14%, p < 0.05). In
addition, insulin AUC0–24h of both the repeated dose and single
dose periods were all significantly higher than the placebo period
(AUC0–24h: repeated dose vs. placebo = 2230.91 ± 128.36 vs.
1478.74 ± 95.62 h·pmol/L, p < 0.01; single dose vs. placebo =
1986.54± 90.88 vs. 1478.74± 95.62 h·pmol/L, p < 0.01).
Interestingly, an increase in glucagon level corresponding to
the Tmax of GABA was also observed (Figure 2C). Particularly,
the glucagon AUC0–4h (fasting period) in the repeated dose
period, as well as in the single dose period, were statistically
higher than that of the placebo period (AUC0–4h: repeated dose
vs. placebo= 65.46 ± 4.33 vs. 48.50 ± 4.83 h·pmol/L, p < 0.01;
single dose vs. placebo= 59.71± 3.68 vs. 48.50± 4.83 h·pmol/L,
p < 0.05). However, glucagon AUC0–24h showed no difference
among the three periods.
Notably, no significant difference of the insulin to glucagon
ratio AUC0–4h or AUC0–24h was observed among the three
periods. Similarly, there was no significant difference in the levels
of active GLP-1 AUC0–24h or AUC0–4h noted among the three
periods (Supplementary Figure 1).
While there was no significant difference of C-peptide
AUC0–24h among the three periods, there was a significant
difference of AUC0–4h between the repeated dose and placebo
periods (Supplementary Figure 2, repeated dose vs. placebo =
8.83± 0.57 vs. 6.51± 0.58 h·pmol/L, p < 0.01).
In order to evaluate whether GABA exerts glycemic regulatory
effects, we measured circulating levels of glycated albumin. The
glycated albumin on day 23 was significantly lower than those on
day 15 and day−2 (Figure 3, day 23 vs. day 15= 10.73± 0.27 vs.
11.82 ± 0.23 %, p < 0.01; day 23 vs. day −2 = 10.73 ± 0.27 vs.
12.18± 0.26%, p < 0.01).
There were no significant differences in the PD parameters
observed between male and female volunteers.
Safety Evaluation
Adverse events following GABA or placebo administration are
presented in Table 2. The most frequently reported adverse
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FIGURE 2 | Concentration-time profiles of blood glucose, insulin and glucagon. The concentration-time curves of blood glucose, insulin, and glucagon in the
three periods (A–C), data are expressed as percent variation of baseline and presented as mean±SE. **p < 0.01 vs. placebo. *p < 0.05 vs. placebo.
FIGURE 3 | Profiles of glycated albumin. The glycated albumin levels on
day 2, 15, and 23 are shown as mean ± SE. **p < 0.01 vs. placebo;
##p < 0.01 vs. single dose.
events, which appeared to be related to the dosing regimens
i.e., single dosing vs. repeated dosing were sore throat, throat
burning, a skin burning sensation, headache, and dizziness. There
were higher occurrences/frequencies of adverse events in the
repeated dose period as compared to the single dose period,
suggesting a dose, and duration dependency. However, there
were no clinically relevant changes in all subjects in vital signs,
ECG parameters, and physical examination. Safety laboratory
measurements such as hematology, biochemistry, and urinalysis
were all in normal ranges; except for four male volunteers
that had slightly elevated alanine transaminase (ALT) and
aspartate aminotransferase (AST) levels. This elevation of liver
enzymes, however, was transient, without symptoms. Without
changes of other biochemical indices of liver function such as
bilirubin, in all cases, the ALT returned to the normal range
without intervention at follow-up visit (Supplementary Table 2).
There were no severe adverse events observed during the
study.
DISCUSSION
Preclinical studies by us and others reveal that GABA exerts anti-
diabetic effects in several T1D mouse models due to its dual
actions on β-cells and the immune system (Tian et al., 2004, 2013,
2014; Soltani et al., 2011; Purwana et al., 2014). This includes
Frontiers in Pharmacology | www.frontiersin.org 6 November 2015 | Volume 6 | Article 260
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TABLE 2 | Clinical and laboratory toxicity.
Placebo Single-dose Repeated-dose
period (D1–D2) period (D15–D16) period (D22–D30)
n (%) e n (%) e n (%) e
Dry pharynx 4 36 7
Sore throat 8 73 22
Throat
burning
4 36 12
Headache 5 45 8
Jaw pain 1 9 1
Neck pain 2 18 3
Dizziness 3 27 3 2 18 5
Poor sleep 4 36 4
Palpitation 2 18 2
Chest
stuffiness
3 27 5
Fatigue 1 9 1
Nausea 1 9 1
Skin needling
sensation
3 27 3
Skin burning
sensation
3 27 8
Limb
numbness
4 36 9
Limb pain 1 9 1
Thirsty 1 9 1
ALT 4 36 8
AST 4 36 8
n, Number of subjects; e, number of adverse events; %, proportion of subjects having the
event.
protection against β-cell apoptosis, β-cell regenerative effects,
and anti-inflammatory effects. Importantly, GABA appears to act
similarly on human and rodent cells, including xenotranplated
human islet cells (Tian et al., 2013; Purwana et al., 2014). These
studies suggest that GABA may be an effective therapeutic agent
for treating T1D. However, there is little information available
on GABA pharmacokinetics in humans, and to address this
issue we investigated the effects of GABA in healthy volunteers.
In this open-labeled, three-period, self-controlled study, we
demonstrate that oral administration of GABA is effective and
modulates circulating islet hormonal levels in healthy subjects.
We found that GABA reached peak concentration in the
circulation after 1 ∼ 1.5 h (Table 1) oral administration and
remained increased for several hours. We observed that after
oral GABA administration at a repeated daily dosing (2 g ×
3) for consecutive 7 days, steady-state conditions appeared to
be attained, which were accompanied by a 1/2 h shortened
Tmax and a higher Cmax than that in the single dose period.
As noted, previous studies (Petty et al., 1987) demonstrated
that plasma GABA levels were not affected by gender, diet,
exercise, and diurnal rhythm, which suggests that GABA has
a reasonable stability for clinical pharmacological purposes.
GABA is known to be metabolized by GABA transaminase
enzyme (GABA + pyruvate = succinic semialdehyde + alanine;
GABA + 2-oxoglutarate = succinic semialdehyde + glutamate;
Bown and Shelp, 1997). However, these transamination products
of GABA have no known pharmacological effects. There was
nearly no accumulation noted after a three-daily dosing for a
consecutive 7 days of oral administration, and with no severe
adverse event observed in the healthy volunteers during the study
course, it implies the possibility of long-term oral GABA clinical
application.
GABA induced a dose-dependent increase in the fasting
(8:00 AM–12:00 AM) and postprandial insulin secretion. GABA
stimulated insulin secretion in humans, which is in accord
with the higher c-peptide AUC0–4h observed in the repeated
dose period. Indeed, in vitro studies using isolated human
islets recently showed that GABA dose-dependently increased
insulin secretion in a GABA receptor dependent manner
(Prud’homme et al., 2013). In accord with this, GABA induced
β-cell membrane depolarization in rodent islets (Wendt et al.,
2004; Soltani et al., 2011) and human islets (Braun et al.,
2010) through A-type GABA receptor (GABAAR) dependent
opening of the voltage dependent Ca2+ channel (Braun et al.,
2010; Purwana et al., 2014). It induced membrane depolarizing
effects in β-cells, which contrasts with its hyperpolarizing effects
in the pancreatic α-cells (Rorsman et al., 1989; Xu et al.,
2006).
Glucagon is an important hormone that counterbalances
insulin actions on blood glucose homeostasis by stimulating
hepatic glycogenolysis and gluconeogenesis (Gromada et al.,
2007; Bansal and Wang, 2008). In vitro studies showed that
while GABA enhances insulin secretion in β-cells, it suppresses
glucagon release from the α-cells (Rorsman et al., 1989; Xu
et al., 2006; Braun et al., 2010; Soltani et al., 2011; Purwana
et al., 2014). However, in this study we found that GABA
increases the circulating levels of both insulin and glucagon,
and that the ratio of insulin to glucagon was not altered.
The reason for this discrepancy between in vitro and in vivo
results is unclear, and requires further investigation. However, we
postulate that this represents a normal physiological response to
control blood glucose levels. Indeed, blood glucose levels were
not significantly changed in healthy subjects upon oral GABA
administration under the fasting conditions, consistent with the
notion that elevated glucagon levels countered the action of
insulin.
GLP-1 is an important incretin hormone in the regulation
of glucose homeostasis (Campbell and Drucker, 2013). We
therefore examined if oral GABA administration affects
circulating GLP-1 levels in the healthy subjects. Under fasting
conditions, the circulating GLP-1 levels were relatively constant,
and there were significant increase in postprandial active
circulating GLP-1 levels (both lunch and supper) in the subjects.
Notably, oral GABA administration (either single or repeated
dose) had no significant effects on the active GLP-1. It is
interesting to note that some previous in vitro studies suggest
potential reciprocal interactions between GLP-1 and GABA
(Gameiro et al., 2005; Wang et al., 2007), Nevertheless, our data
suggested that at least under in vivo conditions, oral GABA
administration at the present regime did not change active
GLP-1 levels in healthy humans.
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GABA significantly decreased glycated albumin levels after
oral administration in repeated dosing (but not the single dose).
Glycated albumin is an indicator of relatively recent (1–2 week)
changes in blood glucose and thus has been considered as an
indication of glycemic control (Inaba et al., 2007; Koga and
Kasayama, 2010). Our results suggest that GABA administration
might improve glycemic control. However, blood glucose levels
monitored at least on day 1, 8, 22 (placebo, single dose, repeated
dose) showed no changes between the three groups. Therefore,
there is a possibility that GABA reduced glycated albumin levels
through biochemical mechanisms other than blood glucose.
Further studies are warranted to investigate the underlying
mechanism of action.
There were no cases of hypoglycemia resulting from
oral GABA administration in this study. Furthermore,
although there were some transient adverse effects which
appeared to be dose and duration dependency, there were
no severe adverse events found during the entire course of
study.
To our knowledge, this is the first clinical study investigating
the pharmacokinetics of GABA in healthy subjects. A limitation
was the lack of dose escalation to determine the optimal
dose of GABA in humans. A future double-blind, randomized,
placebo-controlled study is required to determine the optimal
dose of GABA in humans, in either healthy or diabetic
conditions.
In summary, orally administered GABA is rapidly absorbed by
the gastrointestinal tract and remains elevated in the circulation
for hours. It exerts stimulatory effects on insulin (and c-peptide)
secretion, raising the possibility of its use in the treatment
of diabetes. However, in healthy subjects it has no effects on
instantaneous blood glucose levels. This may in part be attributed
to GABA-induced counter regulatory mechanisms, especially
elevated glucagon, which prevent hypoglycemia in the face
of increased insulin levels. Our study was limited to healthy
subjects, and the effects of GABA in diabetic patients may be
different, and will be investigated in future studies. In terms of
dosage, our findings support a three-daily dosing scheme. Since
GABA targets diabetes in the key areas of islet-cell protection,
regeneration, and immunotherapy, this study provides valid
pharmacokinetics parameters to investigate its actions in diabetic
subjects.
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